Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HUMAN TUMOR XENOGRAFTS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 133 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Khokhar, NZ; She, Y; Rusch, VW; Sirotnak, FM
      Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: Further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums

      CLINICAL CANCER RESEARCH
    2. Guichard, S; Montazeri, A; Chatelut, E; Hennebelle, I; Bugat, R; Canal, P
      Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation

      CLINICAL CANCER RESEARCH
    3. Kruczynski, A; Hill, BT
      Vinflunine, the latest Vinca alkaloid in clinical development - A review of its preclinical anticancer properties

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    4. Bonasera, TA; Ortu, G; Rozen, Y; Krais, R; Freedman, NMT; Chisin, R; Gazit, A; Levitzki, A; Mishani, E
      Potential F-18-labeled biomarkers for epidermal growth factor receptor tyrosine kinase

      NUCLEAR MEDICINE AND BIOLOGY
    5. Pratesi, G; Monestiroli, SV
      Preclinical evaluation of new anthracyclines

      CURRENT MEDICINAL CHEMISTRY
    6. Perego, P; Corna, E; De Cesare, M; Gatti, L; Polizzi, D; Pratesi, G; Supino, R; Zunino, F
      Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines

      CURRENT MEDICINAL CHEMISTRY
    7. Chastagner, P; Kozin, SV; Taghian, A
      Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    8. Struck, RF; Tiwari, A; Friedman, HS; Keir, S; Morgan, LR; Waud, WR
      Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolite of penclomedine

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    9. Keir, ST; Hausheer, F; Lawless, AA; Bigner, DD; Friedman, HS
      Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    10. Riccardi, A; Meco, D; Ferlini, C; Servidei, T; Carelli, G; Segni, G; Manzotti, C; Riccardi, R
      In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    11. Baumann, M; Petersen, C; Wolf, J; Schreiber, A; Zips, D
      No evidence for a different magnitude of the time factor for continuously fractionated irradiation and protocols including gaps in two human squamouscell carcinoma in nude mice

      RADIOTHERAPY AND ONCOLOGY
    12. Supino, R; Polizzi, D; Pavesi, R; Pratesi, G; Guano, F; Capranico, G; Palumbo, M; Sissi, C; Richter, S; Beggiolin, G; Menta, E; Pezzoni, G; Spinelli, S; Torriani, D; Carenini, N; Dal Bo, L; Facchinetti, F; Tortereto, M; Zunino, F
      A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts

      ONCOLOGY
    13. Stephen, AE; Masiakos, PT; Segev, DL; Vacanti, JP; Donahoe, PK; MacLaughlin, DT
      Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    14. Burger, AM; Hartung, G; Stehle, G; Sinn, H; Fiebig, HH
      Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo

      INTERNATIONAL JOURNAL OF CANCER
    15. Cassinelli, G; Supino, R; Perego, P; Polizzi, D; Lanzi, C; Pratesi, G; Zunino, F
      A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

      INTERNATIONAL JOURNAL OF CANCER
    16. De Cesare, M; Pratesi, G; Perego, P; Carenini, N; Tinelli, S; Merlini, L; Penco, S; Pisano, C; Bucci, F; Vesci, L; Pace, S; Capocasa, F; Carminati, P; Zunino, F
      Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin

      CANCER RESEARCH
    17. Watanabe, Y; Koi, M; Hemmi, H; Hoshai, H; Noda, K
      A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer

      BRITISH JOURNAL OF CANCER
    18. Burger, AM; Mengs, U; Schuler, JB; Fiebig, HH
      Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro

      ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
    19. Sabel, MS; Conway, TF; Chen, FA; Bankert, RB
      Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice

      JOURNAL OF IMMUNOTHERAPY
    20. Krug, LM; Ng, KK; Kris, MG; Miller, VA; Tong, W; Heelan, RT; Leon, L; Leung, D; Kelly, J; Sirotnak, FM
      Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate

      CLINICAL CANCER RESEARCH
    21. Polizzi, D; Pratesi, G; Monestiroli, S; Tortoreto, M; Zunino, F; Bombardelli, E; Riva, A; Morazzoni, P; Colombo, T; D'Incalci, M; Zucchetti, M
      Oral efficacy and bioavailability of a novel taxane

      CLINICAL CANCER RESEARCH
    22. Kang, N; Hamilton, S; Odili, J; Wilson, G; Kupsch, J
      In vivo targeting of malignant melanoma by (125)iodine- and (99m)technetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen

      CLINICAL CANCER RESEARCH
    23. Padron, JM; van der Wilt, CL; Smid, K; Smitskamp-Wilms, E; Backus, HHJ; Pizao, PE; Giaccone, G; Peters, GJ
      The multilayered postconfluent cell culture as a model for drug screening

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    24. Liu, CN; Ferdinandi, ES; Ely, G; Joshi, SS
      Virulizin (R)-2 gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts

      INTERNATIONAL JOURNAL OF ONCOLOGY
    25. Fiebig, HH; Dengler, W; Hendriks, HR
      No evidence of tumor growth stimulation in human tumors in vitro followingtreatment with recombinant human growth hormone

      ANTI-CANCER DRUGS
    26. Yang, J; Liu, A; Dougherty, C; Chen, XY; Guzman, R; Nandi, S
      Beware of contaminating mouse cells in human xenografts from nude mice

      ANTICANCER RESEARCH
    27. Reilly, RM; Kiarash, R; Sandhu, J; Lee, YW; Cameron, RG; Hendler, A; Vallis, K; Gariepy, J
      A comparison of EGF and MAb 528 labeled with In-111 for imaging human breast cancer

      JOURNAL OF NUCLEAR MEDICINE
    28. Tomera, JF
      Mesothelioma: Drug treatment and other interventions

      DRUGS OF TODAY
    29. Jeuken, JWM; Sprenger, SHE; Wesseling, P; Bernsen, HJJA; Suijkerbuijk, RF; Roelofs, F; Macville, MVE; Gilhuis, HJ; van Overbeeke, JJ; Boerman, RH
      Genetic reflection of glioblastoma biopsy material in xenografts: characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization

      JOURNAL OF NEUROSURGERY
    30. Figgitt, DP; Wiseman, LR
      Docetaxel - An update of its use in advanced breast cancer

      DRUGS
    31. Cusack, JC; Liu, R; Baldwin, AS
      Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappa B activation

      CANCER RESEARCH
    32. Zhou, R; Bansal, N; Leeper, DB; Glickson, JD
      Intracellular acidification of human melanoma xenografts by the respiratory inhibitor m-iodobenzylguanidine plus hyperglycemia: A P-31 magnetic resonance spectroscopy study

      CANCER RESEARCH
    33. Kolfschoten, GM; Hulscher, TM; Pinedo, HM; Boven, E
      Drug resistance features and S-phase fraction as possible determinants fordrug response in a panel of human ovarian cancer xenografts

      BRITISH JOURNAL OF CANCER
    34. Kruczynski, A; Etievant, C; Perrin, D; Imbert, T; Colpaert, F; Hill, BT
      Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases

      BRITISH JOURNAL OF CANCER
    35. Pratesi, G; Polizzi, D; Perego, P; Dal Bo, L; Zunino, F
      Bcl-2 phosphorylation in a human breast carcinoma xenograft: A common event in response to effective DNA-damaging drugs

      BIOCHEMICAL PHARMACOLOGY
    36. Zunino, F; Cassinelli, G; Polizzi, D; Perego, P
      Molecular mechanisms of resistance to taxanes and therapeutic implications

      DRUG RESISTANCE UPDATES
    37. Line, BR; Feustel, PJ; Festin, SM; Andersen, TT; Dansereau, RN; Lukasiewicz, RL; Zhu, SJ; Bennett, JA
      Scintigraphic detection of breast cancer xenografts with Tc-99m natural and recombinant human alpha-fetoprotein

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    38. Mattern, J; Koomagi, R; Volm, M
      Biological characterization of subgroups of squamous cell lung carcinomas

      CLINICAL CANCER RESEARCH
    39. Sandstrom, P; Johansson, A; Ullen, A; Rathsman, S; Riklund-Ahlstrom, K; Stigbrand, T
      Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting

      CLINICAL CANCER RESEARCH
    40. Furman, WL; Stewart, CF; Poquette, CA; Pratt, CB; Santana, VM; Zamboni, WC; Bowman, LC; Ma, MK; Hoffer, FA; Meyer, WH; Pappo, AS; Walter, AW; Houghton, PJ
      Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

      JOURNAL OF CLINICAL ONCOLOGY
    41. Kinuya, S; Yokoyama, K; Hiramatsu, T; Tega, H; Tanaka, K; Konishi, S; Shuke, N; Aburano, T; Watanabe, N; Takayama, T; Michigishi, T; Tonami, N
      Combination radioimmunotherapy with local hyperthermia: increased deliveryof radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts

      CANCER LETTERS
    42. Taghian, AG; Suit, HD
      Animal systems for translational research in radiation oncology

      ACTA ONCOLOGICA
    43. Howard, RB; Mullen, JBM; Pagura, ME; Johnston, MR
      Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat

      CLINICAL & EXPERIMENTAL METASTASIS
    44. Hardman, WE; Moyer, MP; Cameron, IL
      Efficacy of treatment of colon, lung and breast human carcinoma xenograftswith: Doxorubicin, cisplatin, irinotecan or topotecan

      ANTICANCER RESEARCH
    45. Baumann, M; Petersen, C; Schulz, P; Baisch, H
      Impact of overall treatment time on local control of slow growing human GLsquamous cell carcinoma in nude mice treated by fractionated irradiation

      RADIOTHERAPY AND ONCOLOGY
    46. Boland, I; Vassal, G; Morizet, J; Terrier-Lacombe, MJ; Valteau-Couanet, D; Kalifa, C; Hartmann, O; Gouyette, A
      Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations

      BRITISH JOURNAL OF CANCER
    47. VANDEVRIE W; MARQUET RL; STOTER G; DEBRUIJN EA; EGGERMONT AMM
      IN-VIVO MODEL SYSTEMS IN P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE

      Critical reviews in clinical laboratory sciences
    48. TOKUNAGA T; KIJIMA H; OSHIKA Y; FUKUSHIMA Y; ABE Y; OHNISHI Y; YAMAZAKI H; TSUCHIDA T; MAKUUCHI H; TAMAOKI N; UEYAMA Y; NAKAMURA M
      ABERRANT ISOFORM OF VASCULAR ENDOTHELIAL GROWTH-FACTOR-189 EXPRESSIONIS CORRELATED WITH XENOTRANSPLANTABILITY OF HUMAN ESOPHAGEAL CANCER

      Oncology Reports
    49. BREISTOL K; HENDRIKS HR; BERGER DP; LANGDON SP; FIEBIG HH; FODSTAD O
      THE ANTITUMOR-ACTIVITY OF THE PRODRUG N-L-LEUCYL-DOXORUBICIN AND ITS PARENT COMPOUND DOXORUBICIN IN HUMAN TUMOR XENOGRAFTS

      European journal of cancer
    50. HOUGHTON PJ; STEWART CF; THOMPSON J; SANTANA VM; FURMAN WL; FRIEDMAN HS
      PRECLINICAL AND CLINICAL-RESULTS WITH IRINOTECAN - EXTENDING PRINCIPLES LEARNED IN MODEL SYSTEMS TO CLINICAL-TRIALS DESIGN

      Oncology
    51. KUMAZAWA E; JIMBO T; OCHI Y; TOHGO A
      POTENT AND BROAD ANTITUMOR EFFECTS OF DX-8951F, A WATER-SOLUBLE CAMPTOTHECIN DERIVATIVE, AGAINST VARIOUS HUMAN TUMORS XENOGRAFTED IN NUDE-MICE

      Cancer chemotherapy and pharmacology
    52. KRUCZYNSKI A; COLPAERT F; TARAYRE JP; MOUILLARD P; FAHY J; HILL BT
      PRECLINICAL IN-VIVO ANTITUMOR-ACTIVITY OF VINFLUNINE, A NOVEL FLUORINATED VINCA ALKALOID

      Cancer chemotherapy and pharmacology
    53. VASSAL G; PONDARRE C; BOLAND I; CAPPELLI C; SANTOS A; THOMAS C; LUCCHI E; IMADALOU K; PEIN F; MORIZET J; GOUYETTE A
      PRECLINICAL DEVELOPMENT OF CAMPTOTHECIN DERIVATIVES AND CLINICAL-TRIALS IN PEDIATRIC ONCOLOGY

      Biochimie
    54. CHIBA Y; KUBOTA T; WATANABE M; MATSUZAKI SW; OTANI Y; TERAMOTO T; MATSUMOTO Y; KOYA K; KITAJIMA M
      MKT-077, LOCALIZED LIPOPHILIC CATION - ANTITUMOR-ACTIVITY AGAINST HUMAN TUMOR XENOGRAFTS SERIALLY TRANSPLANTED INTO NUDE-MICE

      Anticancer research
    55. APPOLD S; BAUMANN M; PETERSEN C; HORN K; EICHHORN F
      COMPARISON OF THE RESPONSE OF HUMAN FADU SQUAMOUS-CELL CARCINOMA IN NUDE-MICE AFTER HYPOFRACTIONATED-ACCELERATED REGIMENS AND CURATIVE FRACTIONATION SCHEDULES

      Strahlentherapie und Onkologie
    56. ZALATNAI A; BOCSI J; TIMAR F; BABO S
      ESTABLISHMENT AND CHARACTERIZATION OF A NEW TRANSPLANTABLE PANCREATIC-CANCER XENOGRAFT (PZX-5) IN IMMUNOSUPPRESSED MICE

      International journal of pancreatology
    57. NODA T; WATANABE T; KOHDA A; HOSOKAWA S; SUZUKI T
      CHRONIC EFFECTS OF A NOVEL SYNTHETIC ANTHRACYCLINE DERIVATIVE (SM-5887) ON NORMAL HEART AND DOXORUBICIN-INDUCED CARDIOMYOPATHY IN BEAGLE DOGS

      Investigational new drugs
    58. THOMPSON J; STEWART CF; HOUGHTON PJ
      ANIMAL-MODELS FOR STUDYING THE ACTION OF TOPOISOMERASE-I TARGETED DRUGS

      Biochimica et biophysica acta, N. Gene structure and expression
    59. ROCKWELL S
      EXPERIMENTAL RADIOTHERAPY - A BRIEF-HISTORY

      Radiation research
    60. ROBERT J; RIVORY L
      PHARMACOLOGY OF IRINOTECAN

      Medicamentos de actualidad
    61. Chabot, GG; Robert, J; Lokiec, F; Canal, P
      Irinotecan pharmacokinetics

      BULLETIN DU CANCER
    62. TURNER JH; ROSE AH; GLANCY RJ; PENHALE WJ
      ORTHOTOPIC XENOGRAFTS OF HUMAN-MELANOMA AND COLONIC AND OVARIAN-CARCINOMA IN SHEEP TO EVALUATE RADIOIMMUNOTHERAPY

      British Journal of Cancer
    63. BOUCHER Y; BREKKEN C; NETTI PA; BAXTER LT; JAIN RK
      INTRATUMORAL INFUSION OF FLUID - ESTIMATION OF HYDRAULIC CONDUCTIVITYAND IMPLICATIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS

      British Journal of Cancer
    64. Boven, E; Pinedo, HM; van Hattum, AH; Scheffer, PG; Peters, WHM; Erkelens, CAM; Schluper, HMM; Kuiper, CM; van Ark-Otte, J; Giaccone, G
      Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening

      BRITISH JOURNAL OF CANCER
    65. OSTROVSKAYA LA; ULYANOVA NM; FOMINA MM; RYKOVA VA; KONRADOV AA; BRIN EF; GORBUNOVA NV; GORBACHEVA LB; KHALEEV DV
      KINETICS OF DEVELOPMENT OF HUMAN-MELANOMA XENOGRAFTS IN IMMUNOSUPPRESSED ANIMALS

      Izvestia Akademii nauk SSSR. Seria biologiceskaa
    66. DEBRUIJN P; VERWEIJ J; LOOS WJ; NOOTER K; STOTER G; SPARREBOOM A
      DETERMINATION OF IRINOTECAN (CPT-11) AND ITS ACTIVE METABOLITE SN-38 IN HUMAN PLASMA BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION

      Journal of chromatography B. Biomedical sciences and applications
    67. THOMPSON J; ZAMBONI WC; CHESHIRE PJ; LUTZ L; LUO XL; LI YL; HOUGHTON JA; STEWART CF; HOUGHTON PJ
      EFFICACY OF SYSTEMIC ADMINISTRATION OF IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS

      Clinical cancer research
    68. DREES M; DENGLER WA; ROTH T; LABONTE H; MAYO J; MALSPEIS L; GREVER M; SAUSVILLE EA; FIEBIG HH
      FLAVOPIRIDOL (L86-8275) - SELECTIVE ANTITUMOR-ACTIVITY IN-VITRO AND ACTIVITY IN-VIVO FOR PROSTATE CARCINOMA-CELLS

      Clinical cancer research
    69. KUNZSCHUGHART LA; FREYER JP
      ADAPTATION OF AN AUTOMATED SELECTIVE DISSOCIATION PROCEDURE TO 2 NOVEL SPHEROID TYPES

      In vitro cellular & developmental biology. Animal
    70. KAIHARA C; MATSUZAKI M; TAGUCHI H; MATSUZAKI WS; KUBOTA T
      THE CLINICAL-APPLICATION OF AN ATP ASSAY TO PREDICT THE CHEMOSENSITIVITY OF GASTRIC-CANCER

      Oncology Reports
    71. BROWN RS; KAMINSKI MS; FISHER SJ; CHANG AE; WAHL RL
      INTRATUMORAL MICRODISTRIBUTION OF [I-131] MB-1 IN PATIENTS WITH B-CELL LYMPHOMA FOLLOWING RADIOIMMUNOTHERAPY

      Nuclear medicine and biology
    72. MITCHELL BS; SCHUMACHER U
      USE OF IMMUNODEFICIENT MICE IN METASTASIS RESEARCH

      British journal of biomedical science
    73. BIGIONI M; SALVATORE C; PALMA C; MANZINI S; ANIMATI F; LOMBARDI P; PRATESI G; SUPINO R; ZUNINO F
      CYTOTOXIC AND ANTITUMOR-ACTIVITY OF MEN-10710, A NOVEL ALKYLATING DERIVATIVE OF DISTAMYCIN

      Anti-cancer drugs
    74. THOMPSON J; ZAMBONI WC; CHESHIRE PJ; RICHMOND L; LUO XL; HOUGHTON JA; STEWART CF; HOUGHTON PJ
      EFFICACY OF ORAL IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS

      Anti-cancer drugs
    75. SHARKEY RM; BEHR TM; MATTES MJ; STEIN R; GRIFFITHS GL; SHIH LB; HANSEN HJ; BLUMENTHAL RD; DUNN RM; JUWEID ME; GOLDENBERG DM
      ADVANTAGE OF RESIDUALIZING RADIOLABELS FOR AN INTERNALIZING ANTIBODY AGAINST THE B-CELL LYMPHOMA ANTIGEN, CD22

      Cancer immunology and immunotherapy
    76. CHABOT GG
      CLINICAL PHARMACOKINETICS OF IRINOTECAN

      Clinical pharmacokinetics
    77. ZUNINO F; POLIZZI D; PRATESI G
      CAMPTOTHECINS - MECHANISM OF ACTION AND PRECLINICAL STUDIES

      Tumori
    78. CHRISTIAN MC; PLUDA JM; HO PTC; ARBUCK SG; MURGO AJ; SAUSVILLE EA
      PROMISING NEW AGENTS UNDER DEVELOPMENT BY THE DIVISION OF CANCER-TREATMENT, DIAGNOSIS, AND CENTERS OF THE NATIONAL-CANCER-INSTITUTE

      Seminars in oncology
    79. VASSAL G; BOLAND I; SANTOS A; BISSERY MC; TERRIERLACOMBE MJ; MORIZET J; SAINTEROSE C; LELLOUCHTUBIANA A; KALIFA C; GOUYETTE A
      POTENT THERAPEUTIC ACTIVITY OF IRINOTECAN (CPT-11) AND ITS SCHEDULE DEPENDENCY IN MEDULLOBLASTOMA XENOGRAFTS IN NUDE-MICE

      International journal of cancer
    80. ROFSTAD EK; LYNG H
      XENOGRAFT MODEL SYSTEMS FOR HUMAN-MELANOMA

      Molecular medicine today
    81. HOUGHTON JA; CHESHIRE PJ; HALLMAN JD; LUTZ L; LUO XL; LI YL; HOUGHTON PJ
      EVALUATION OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL OR ETOPOSIDE IN XENOGRAFT MODELS OF COLON ADENOCARCINOMA AND RHABDOMYOSARCOMA

      Clinical cancer research
    82. OREILLY S; ROWINSKY EK
      THE CLINICAL STATUS OF IRINOTECAN (CPT-11), A NOVEL WATER-SOLUBLE CAMPTOTHECIN ANALOG - 1996

      Critical reviews in oncology/hematology
    83. BISSERY MC; VRIGNAUD P; LAVELLE F; CHABOT GG
      EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE

      Anti-cancer drugs
    84. VOLM M; MATTERN J
      RESISTANCE MECHANISMS AND THEIR REGULATION IN LUNG-CANCER

      Critical reviews in oncogenesis
    85. EIL A; DIMITRAKOPOULOUSTRAUSS A; TILGEN W; OBERDORFER F; DOLL J; STRAUSS LG
      FUNCTIONAL IMAGING WITH POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITHMALIGNANT-MELANOMA

      Onkologie
    86. LAWRENCE TS; CHANG EY; DAVIS MA; STETSON PL; ENSMINGER WD
      EFFECT OF IRRADIATION ON BROMODEOXYURIDINE INCORPORATION IN HUMAN COLON-CANCER XENOGRAFTS

      International journal of radiation oncology, biology, physics
    87. SHEEHAN PFJ; BAKER T; TUTTON PJM; BARKLA DH
      EFFECTS OF HISTAMINE AND 5-HYDROXYTRYPTAMINE ON THE GROWTH-RATE OF XENOGRAFTED HUMAN BRONCHOGENIC CARCINOMAS

      Clinical and experimental pharmacology and physiology
    88. KHAN MZ; MCNICOL AM; FRESHNEY RI
      TUMORIGENICITY, INVASION AND METASTASIS OF THE SMALL-CELL LUNG-CANCERCELL-LINE NCI-H69 AND 2 DERIVATIVE LINES MOG-H69V AND MOG-H69VZ

      Anticancer research
    89. STERN S; GUICHARD M
      EFFICACY OF AGENTS COUNTERACTING HYPOXIA IN FRACTIONATED RADIATION REGIMES

      Radiotherapy and oncology
    90. THOMAS CD; STERN S; CHAPLIN DJ; GUICHARD M
      TRANSIENT PERFUSION AND RADIOSENSITIZING EFFECT AFTER NICOTINAMIDE, CARBOGEN, AND PERFLUBRON EMULSION ADMINISTRATION

      Radiotherapy and oncology
    91. CLARKE R
      HUMAN BREAST-CANCER CELL-LINE XENOGRAFTS AS MODELS OF BREAST-CANCER -THE IMMUNOBIOLOGIES OF RECIPIENT MICE AND THE CHARACTERISTICS OF SEVERAL TUMORIGENIC CELL-LINES

      Breast cancer research and treatment
    92. LAVELLE F; BISSERY MC; ANDRE S; ROQUET F; RIOU JF
      PRECLINICAL EVALUATION OF CPT-11 AND ITS ACTIVE METABOLITE SN-38

      Seminars in oncology
    93. ARMAND JP
      CPT-11 - CLINICAL-EXPERIENCE IN PHASE-I STUDIES

      Seminars in oncology
    94. ROUGIER P; BUGAT R
      CPT-11 IN THE TREATMENT OF COLORECTAL-CANCER - CLINICAL EFFICACY AND SAFETY PROFILE

      Seminars in oncology
    95. WISEMAN LR; MARKHAM A
      IRINOTECAN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL EFFICACY IN THE MANAGEMENT OF ADVANCED COLORECTAL-CANCER

      Drugs
    96. LIU LL; LEE K; WASAN E; GERSON SL
      DIFFERENTIAL SENSITIVITY OF HUMAN AND MOUSE ALKYLTRANSFERASE TO O-6-BENZYLGUANINE USING A TRANSGENIC MODEL

      Cancer research
    97. DANCEY J; EISENHAUER EA
      CURRENT PERSPECTIVES ON CAMPTOTHECINS IN CANCER-TREATMENT

      British Journal of Cancer
    98. GOLDENBERG DM
      CARCINOEMBRYONIC ANTIGEN AS A TARGET CANCER ANTIGEN FOR RADIOLABELED ANTIBODIES - PROSPECTS FOR CANCER IMAGING AND THERAPY

      Tumor biology
    99. HOFS HP; WAGENER DJT; DEVOS D; OTTENHEIJM HCJ; WINKENS HJ; BOVEE PHM; DEGRIP WJ
      ANTITUMOR-ACTIVITY AND RETINOTOXICITY OF ETHYLDESHYDROXY-SPARSOMYCIN IN MICE

      European journal of cancer
    100. DENGLER WA; SCHULTE J; BERGER DP; MERTELSMANN R; FIEBIG HH
      DEVELOPMENT OF A PROPIDIUM IODIDE FLUORESCENCE ASSAY FOR PROLIFERATION AND CYTOTOXICITY ASSAYS

      Anti-cancer drugs


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/01/21 alle ore 19:02:12